X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (265) 265
Book / eBook (29) 29
Publication (20) 20
Book Review (15) 15
Magazine Article (8) 8
Newspaper Article (4) 4
Book Chapter (3) 3
Dissertation (3) 3
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (91) 91
index medicus (67) 67
hematology (62) 62
male (55) 55
middle aged (55) 55
female (52) 52
adult (49) 49
aged (48) 48
imatinib mesylate (41) 41
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (40) 40
pyrimidines - therapeutic use (37) 37
antineoplastic agents - therapeutic use (35) 35
benzamides (33) 33
nilotinib (32) 32
chronic myeloid leukemia (30) 30
leukemia (28) 28
oncology (28) 28
imatinib (26) 26
piperazines - therapeutic use (26) 26
treatment outcome (26) 26
chronic myelogenous leukemia (25) 25
aged, 80 and over (24) 24
pyrimidines - adverse effects (21) 21
adolescent (20) 20
leukemia, myelogenous, chronic, bcr-abl positive - genetics (20) 20
young adult (20) 20
bcr-abl (19) 19
care and treatment (19) 19
protein kinase inhibitors - therapeutic use (19) 19
follow-up studies (18) 18
antineoplastic agents (17) 17
chronic myeloid-leukemia (17) 17
retrospective studies (17) 17
prognosis (16) 16
protein-tyrosine kinases - antagonists & inhibitors (16) 16
pyrimidines - administration & dosage (16) 16
analysis (15) 15
fusion proteins, bcr-abl - genetics (15) 15
antimitotic agents (14) 14
dasatinib (14) 14
piperazines - adverse effects (14) 14
cml (13) 13
hemic and lymphatic diseases (13) 13
tyrosine kinase inhibitors (13) 13
antineoplastic agents - adverse effects (12) 12
cancer (12) 12
cancer research (12) 12
pyrimidines - pharmacology (12) 12
resistance (12) 12
abridged index medicus (11) 11
drug resistance, neoplasm (11) 11
drug therapy (11) 11
hematology, oncology and palliative medicine (11) 11
philadelphia chromosome (11) 11
therapy (11) 11
transplantation (11) 11
fusion proteins, bcr-abl - antagonists & inhibitors (10) 10
medicine & public health (10) 10
piperazines - pharmacology (10) 10
protein kinase inhibitors - adverse effects (10) 10
research (10) 10
risk factors (10) 10
antineoplastic agents - administration & dosage (9) 9
follow-up (9) 9
mutation (9) 9
tyrosine kinase inhibitor (9) 9
fusion proteins, bcr-abl - metabolism (8) 8
kaplan-meier estimate (8) 8
leukemia, myeloid, chronic-phase - drug therapy (8) 8
reverse transcriptase polymerase chain reaction (8) 8
stem cells (8) 8
transplantation, homologous (8) 8
acute myeloid leukemia (7) 7
chronic myeloid leukaemia (7) 7
clinical trials as topic (7) 7
disease-free survival (7) 7
leukemia, myelogenous, chronic, bcr-abl positive - mortality (7) 7
leukemia, myelogenous, chronic, bcr-abl positive - pathology (7) 7
leukemia, myeloid, acute - therapy (7) 7
myeloid leukemia (7) 7
protein kinase inhibitors - administration & dosage (7) 7
pyrimidines - pharmacokinetics (7) 7
recurrence (7) 7
remission induction (7) 7
time factors (7) 7
versus-host-disease (7) 7
abl tyrosine kinase (6) 6
allogeneic stem cell transplantation (6) 6
clinical trials (6) 6
cytogenetic responses (6) 6
disease (6) 6
disease progression (6) 6
drug administration schedule (6) 6
genetic aspects (6) 6
history (6) 6
imatinib-resistant (6) 6
internal medicine (6) 6
leukemia, myeloid, acute - genetics (6) 6
myelodysplastic syndrome (6) 6
survival analysis (6) 6
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (8) 8
UTL at Downsview - May be requested (8) 8
Online Resources - Online (4) 4
Pontifical Inst. Mediaeval Studies - Library use only (2) 2
St. Michael's College (John M. Kelly) - 2nd Floor (2) 2
Victoria University CRRS - Library use only (2) 2
Art - Library use only (1) 1
Pontifical Inst. Mediaeval Studies - Reference (1) 1
Royal Ontario Museum - Reference Desk (1) 1
St. Michael's College (John M. Kelly) - 3rd Floor (1) 1
St. Michael's College (John M. Kelly) - Rare Book (1) 1
Victoria University CRRS - Rare Book (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (228) 228
French (106) 106
Spanish (4) 4
Italian (3) 3
German (2) 2
Japanese (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drugs, ISSN 0012-6667, 2008, Volume 68, Issue 4, pp. 460 - 461
Journal Article
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2019, Volume 9, Issue 1, pp. 1 - 13
Leukemia-associated antigens (LAAs) and HLA-I epitopes published previously have shown promise in inducing leukemia-specific T cell responses. However, the... 
Antigens | Myeloid leukemia | CD8 antigen | Leukemia | Mass spectroscopy | Lymphocytes T | Tumor cell lines | Epitopes | Cell differentiation | High-performance liquid chromatography | Immunogenicity | Lymphocytes | Immunotherapy | Histocompatibility antigen HLA
Journal Article
Recent Results in Cancer Research, ISSN 0080-0015, 2018, Volume 212, pp. 69 - 85
With imatinib still being linked to the breakthrough in CML therapy and probably being the most prescribed drug, second-generation TKIs are increasingly... 
Nilotinib | CML | TKI
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 4533 - 4533
Abstract Musashi 2 (also known as MSI2), a mRNA binding protein is reported to control critical stem cell fate decisions by binding to the 3’untranslated... 
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 3107 - 3107
Abstract BACKGROUND: Ruxolitinib is a potent JAK1/JAK2 inhibitor that has proved superior to placebo and best available therapy in the phase 3 COMFORT studies... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 3157 - 3157
Abstract To date no single molecular biomarker, with proven clinical utility, that is predictive and identifies patients with more aggressive chronic myeloid... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 4534 - 4534
Abstract Background: The safety profile of each BCR-ABL1– targeted tyrosine kinase inhibitor (TKI) used to treat chronic myeloid leukemia (CML) is unique and... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2010, Volume 362, Issue 24, pp. 2251 - 2259
The treatment of chronic myeloid leukemia (CML) achieved a great leap forward with the development of imatinib, a BCR-ABL kinase inhibitor. Alterations in the... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, GENERAL & INTERNAL | PHASE CML-CP | MOLECULAR RESPONSES | UP SUSTAINED SURVIVAL | 800 MG | HARMONIZING CURRENT METHODOLOGY | FOLLOW-UP | PATIENTS RECEIVING IMATINIB | PATIENTS PTS | BCR-ABL TRANSCRIPTS | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Blast Crisis - prevention & control | Protein Kinase Inhibitors - adverse effects | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Kaplan-Meier Estimate | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Benzamides | Nilotinib | Antiviral agents | Safety and security measures | Chronic myeloid leukemia | Drug therapy | Comparative analysis | Clinical trials | Drug dosages | Medical treatment | bcr-abl | pathology | Leukemia | Chronic-Phase | Myeloid | Klinisk medicin | 80 and over | Pyrimidines | administration & dosage | Fusion Proteins | Blast Crisis | drug therapy | Piperazines | Antineoplastic Agents | prevention & control | antagonists & inhibitors | Clinical Medicine | Protein Kinase Inhibitors | adverse effects | therapeutic use
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.